These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34694893)

  • 21. Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
    Gibson CM; Hankey GJ; Nafee T; Welsh RC
    Thromb Haemost; 2018 May; 118(S 01):S34-S44. PubMed ID: 29566416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C; Dai S; Sobieraj DM
    Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
    [No Abstract]   [Full Text] [Related]  

  • 25. Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
    Chang CJ; Cheng CC; Chen YC; Higa S; Huang JH; Chen SA; Chen YJ
    Eur J Pharmacol; 2018 Aug; 833():462-471. PubMed ID: 30017860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
    Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
    Gibson CM; Pinto DS; Chi G; Arbetter D; Yee M; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Burton P; van Eickels M; Korjian S; Daaboul Y; Jain P; Lip GY; Cohen M; Peterson ED; Fox KA
    Circulation; 2017 Jan; 135(4):323-333. PubMed ID: 27881555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
    Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes.
    Wang Z; Zhu LY; Yu LY; Chen WQ; Chen YN; Li Q; Liu Y; Jiao SQ; Zhai ZG; Zhao L; Sun YH
    Thromb Res; 2022 Oct; 218():189-191. PubMed ID: 36087354
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspirin versus P2Y
    Fukaya H; Ako J; Yasuda S; Kaikita K; Akao M; Matoba T; Nakamra M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Heart; 2021 Nov; 107(21):1731-1738. PubMed ID: 34261738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.
    Marín F; Fernández MS; Barón-Esquivias G; Barrios V; Lekuona I; Pérez-Cabeza AI; Masjuan J; Del Vigo ER; Vázquez Rodríguez JM; Freixa-Pamias R; Schilling VR; Arribas F; Priu CR; Sánchez MA
    J Comp Eff Res; 2023 Mar; 12(3):e220049. PubMed ID: 36749006
    [No Abstract]   [Full Text] [Related]  

  • 34. Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1).
    Suzuki S; Yamashita T; Kasai H; Otsuka T; Sagara K
    Thromb Res; 2017 Feb; 150():73-75. PubMed ID: 28043042
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
    Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
    [No Abstract]   [Full Text] [Related]  

  • 36. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    De Backer O; Dangas GD; Jilaihawi H; Leipsic JA; Terkelsen CJ; Makkar R; Kini AS; Veien KT; Abdel-Wahab M; Kim WK; Balan P; Van Mieghem N; Mathiassen ON; Jeger RV; Arnold M; Mehran R; Guimarães AHC; Nørgaard BL; Kofoed KF; Blanke P; Windecker S; Søndergaard L;
    N Engl J Med; 2020 Jan; 382(2):130-139. PubMed ID: 31733182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monotherapy for nonvalvular A-fib with stable CAD?
    Garigan TP; Earwood JS; Poplawski M
    J Fam Pract; 2021 Oct; 70(8):403-407. PubMed ID: 34818177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Problems of anticoagulation therapy in patients with chronic heart failure and atrial fibrillation: role of rivaroxaban].
    Kobalava ZD; Villevalde SV; Troitskaya EA
    Kardiologiia; 2018 SFeb; (S2):33-41. PubMed ID: 29782252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC).
    Tanaka A; Suzuki M; Matsunaga K; Taguchi I; Nakahara S; Chihara A; Oyama JI; Node K
    Hypertens Res; 2020 Jun; 43(6):571-574. PubMed ID: 31925340
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.